Celltrion Applies for Global Phase 3 Clinical Trial of 'Actemra' Biosimilar
[Asia Economy Reporter Hwang Yoon-joo] Celltrion announced on the 17th that it has applied for a Phase 3 clinical trial plan for 'CT-P47,' a biosimilar of the rheumatoid arthritis treatment 'Actemra' (generic name: tocilizumab).
Celltrion began the Phase 1 clinical trial of CT-P47 in July of last year.
Hot Picks Today
Flight Attendant Kneeled to Apologize... China Eastern Airlines Bans Passenger Who Continued to Complain
- An Apartment Once Worth 400 Million Won Nears 1 Billion... "Still Worth It" as 1990s-Born Pangyo Workers Flock to Gyeonggi Gwangju [Report]
- "Didn't Want to Buy a Home"... Seoul Apartment Buyers Flocked to Mid- to Low-Priced Segment After Tax Reform Plan [Real Estate AtoZ]
- "Is It That Time of the Month?" Army Captain Who Sexually Harassed Female Lieutenant... Court Rules Three-Month Suspension Is Lawful
- Musk's Partner Reveals Sudden Breakup Just a Week After Saying "I Love You"
The Phase 3 trial is a study comparing the efficacy, safety, pharmacokinetics, and immunogenicity of CT-P47 and Actemra in a total of 448 rheumatoid arthritis patients across Europe.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
